` TRML (Tourmaline Bio Inc) vs S&P 500 Comparison - Alpha Spread

TRML
vs
S&P 500

Over the past 12 months, TRML has outperformed S&P 500, delivering a return of 10% compared to the S&P 500's 9% growth.

Stocks Performance
TRML vs S&P 500

Loading
TRML
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TRML vs S&P 500

Loading
TRML
S&P 500
Difference
www.alphaspread.com

Performance By Year
TRML vs S&P 500

Loading
TRML
S&P 500
Add Stock

Competitors Performance
Tourmaline Bio Inc vs Peers

S&P 500
TRML
ABBV
AMGN
GILD
VRTX
Add Stock

Tourmaline Bio Inc
Glance View

Market Cap
432.3m USD
Industry
Biotechnology

Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Louisville, Kentucky and currently employs 129 full-time employees. The company went IPO on 2021-05-07. Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The firm is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The firm focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.

TRML Intrinsic Value
Not Available
Back to Top